BBTX Insider Trading Activity and SEC Form 4 Filings
BBTX insider trading summary
Over the past 12 months, insiders at Bambusa Therapeutics, Inc. (BBTX) reported 22 open-market purchases worth $245.2M by 7 insiders and no sales on SEC Form 4. Net insider buying was $245.2M.
Latest BBTX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 2, 2026 | Rajeev M. Shah | Director | Buy | $37.4M (2,335,109 @ $16.00) |
| Nov 2, 2026 | RA Capital Healthcare Fund LP | Director | Buy | $2.6M (164,891 @ $16.00) |
| Nov 2, 2026 | RA Capital Healthcare Fund LP | Director | Buy | $37.4M (2,335,109 @ $16.00) |
| Nov 2, 2026 | Peter Kolchinsky | Director | Buy | $37.4M (2,335,109 @ $16.00) |
| Nov 2, 2026 | Salvia Investment GmbH | Insider | Buy | $6.0M (375,000 @ $16.00) |
| Nov 2, 2026 | Ra Capital Management, L.P. | Insider | Buy | $2.6M (164,891 @ $16.00) |
| Nov 2, 2026 | Helmut Wolfgang Jeggle | Insider | Buy | $6.0M (375,000 @ $16.00) |
| Nov 2, 2026 | Ra Capital Management, L.P. | Insider | Buy | $37.4M (2,335,109 @ $16.00) |
| Nov 2, 2026 | RA Capital Nexus Fund III, L.P. | Director | Buy | $37.4M (2,335,109 @ $16.00) |
| Nov 2, 2026 | RA Capital Nexus Fund III, L.P. | Director | Buy | $2.6M (164,891 @ $16.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.